Research Reports

Key takeaways

The company entered into Change in Control Bonus Payment Agreements with four executives on April 1, 2026.

The agreements cover CEO Dr. George Magrath, CFO Robert Gagnon, COO Joseph Schachle, and CSDO Dr. Ashwath Jayagopal.

The agreements provide for reimbursement of excise taxes under Section 4999 of the Internal Revenue Code in connection with a change in control.

The agreements include provisions for gross-up payments to ensure executives remain in the same after-tax position as if no excise tax had been imposed.

An independent 280G Firm will make determinations regarding gross-up payments, with all fees borne by the company.

The company will control tax contest proceedings and indemnify executives for related taxes and expenses.

Full analysis

Opus Genetics has established Change in Control Bonus Payment Agreements with its four top executives, creating financial protections in the event of a corporate change in control. These agreements specifically address Section 4999 excise taxes that could apply to parachute payments, with the company committing to reimburse executives for these taxes and provide gross-up payments to ensure they remain in the same after-tax position. The agreements establish a framework where an independent 280G Firm makes determinations about required payments, with the company bearing all associated costs and controlling any tax contest proceedings while indemnifying executives. This arrangement reduces potential distractions for executives during change in control scenarios and aligns their financial interests with shareholders in such transactions.

IRD · Opus Genetics, Inc.

Summary

Key takeaways

Full analysis